Changes in the uptake of antiretroviral therapy and survival in people with known duration of UTV infection in Europe: Results from CASCADE

HIV Medicine

Volumn 1, Issue 4, 2000, Pages 224-231

  Porter, K ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Antiretroviral therapy; CD4; Seroconverters; Survival

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; EUROPE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL COOPERATION; MALE; MORTALITY; RISK FACTOR; SEXUAL BEHAVIOR; SURVIVAL; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; EUROPE; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMAN; INTERNATIONAL COOPERATION; MALE; MIDDLE AGE; RISK FACTORS; SEX BEHAVIOR; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0034305946     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2000.00033.x     Document Type: Article

References (42)

1. Volberding PA, Lagakos SW, Grimes JM et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995; 333: 401-407.
2. Concorde Co-ordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-881.
3. Hammer SM, Katzenstein DA, Hughes MD eta}. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to BOO per cubic millimetre. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996; 335: 1081-1090.
4. Saravolatz LD, Winslow DL, Collins G étal. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimetre. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1996; 335: 1099-1106.
5. Delta Co-ordinating Committee. Delta: a randomised doubleblind controlled trial comparing combinations of zidovudine plus didanosine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-291.
6. Hammer SM, Squires KE, Hughes MD eraJ. A controlled trial of two nucleoside analogues plus indinavir in people with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. AIDS Clinical Trials Group 320 Study Team. AT £113) J Med 1997; 337: 725-733.
7. Gulick RM, Mellors JW, Havlir D étal. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-739.
8. Spira R, Marimoutou C, Binquet C, Lacoste D, Dabis F for the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995-97. J Acquir Immune Deβc Syndr 1998; 18: 358-364.
9. Egger M, Hirschel B, Francioli P et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315: 1194-1199.
10. Mocroft A, Vella S, Benfield TL etal. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-1730.
11. Palella FJ Jr, Delaney KM, Moorman AC etal. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N EnglJ Med 1998; 338: 853-860.
12. Detels R, Munoz A, McFarlane G etal. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 17: 1497-1503.
13. UK Register of HIV Seroconverters Steering Committee. The AIDS incubation period in the UK estimated from a national register of HIV seroconverters. AIDS 1998; 12: 659-667.
14. Dorrucci M, Balducci M, Pezzotti P etal. Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. J AIDS 1999; 22: 65-70.
15. Pedersen C, Lindhardt BO, Jensen BO eraJ. Clinical course of primary HIV infection: consequences for subsequent course of infection. BM7 1989; 299: 154-157.
16. Touloumi G, Karafoulidou A, Gialeraki A eraJ. Determinants of progression of HIV infection in a Greek haemophilia cohort followed for up to 16 years after infection. J AIDS 1998; 19: 89-97.
17. Schwartländer B, Bek B, Skarabis H etal. Improvement of the predictive value of CD4+ lymphocyte count by beta 2-microglobulin, immunoglobulin A and erythrocyte sedimentation rate. AIDS 1993; 7: 813-821.
18. Marimoutou C, Chene G, Dabis F, Lacoste D, Salamon R for the Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA). Human immunodeficiency virus infection and AIDS in Aquitaine. 10 years' experience of a hospital information system, 1985-95. Presse Med 1997; 26: 703-710 [in French].
19. Carré N, Meyer L, Boufassa F étal and the SEROCO Study Group. High risk of HIV disease progression after infection through a sexual partner with AIDS. AIDS 1996; 10: 77-80.
20. Pezzotti P, Phillips AN, Dorrucci M etal. Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. BMJ 1996; 313: 583-586.
21. van den Hoek JAR, Coutinho RA, van Haastrecht HJA etal. Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS 1988; 2: 55-60.
22. van Griensven GJP, Tielman RAP, Goudsmit J etal. Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands. Am J Epidemiol 1987; 125: 1048-1057.
23. Eskild A, Magnus P, Brekke T etal. The impact of exposure group on the progression rate to acquired immunodeficiency syndrome. Scand J Infect Dis 1997; 29: 103-109.
24. Dobloug JH, Bruun JN, Skaug K. The early introduction of HIV infection among Norwegians at highest risk. Scand J Infect Dis 1990; 22: 753-754.
25. Montoro JB, Oliveras J, Lorenzo JI etal. An association between clotting factor concentrates use and mortality in human immunodeficiency virus-infected haemophilic patients. Blood 1995;86:2213-2219.
26. Grupo de estudio de seroconvertores de la CAM. Identiβcaciön de factures que afectan a la liistoria natural de la infeccidn par el VIH en una cohorte de personas confecha de seroconversion conocida. Santiago de Compostela, SEISIDA, 1999: CP5-7.
27. Perez-Hoyos S, Avino M, Hemandez I etal. AlDS-free time and survival of an injecting drug users HIV seroconverters cohort. Gac Sanit 1999; 13: 337-345.
28. Brettle RP, McNeil AJ, Burns S étal. Progression of HIV: follow-up of Edinburgh injecting drug users with narrow seroconversion intervals in 1983-85. AIDS 1996; 10: 419-430.
29. Sabin CA, Devereux H, Phillips AN etal. Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. AIDS 1998; 12: 1347-1352.
30. Tindall B, Swanson CE, Cooper DA. Development of AIDS in a cohort of HIV-seropositive homosexual men in Australia. Med JAust 1990; 153: 260-265.
31. Vanhems P, Allard R, Cooper A etal. Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: is the diagnosis too restrictive. Clin Infect Dis 1997; 24: 965-970.
32. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
33. Clayton C, Hills M. Statistical Models in Epidemiology. Oxford, Oxford University Press, 1993.
34. Vanhems P, Lambert J, Cooper DA etal. Acute HIV-1 illness severity and prognosis: a dose response effect. Clin Infect Dis 1998; 26: 323-329.
35. Lindbäck S, Broström Karlsson A, Gaines H. Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 X 106/1, AIDS, and death from AIDS? BMJ 1994; 309: 1535-1537.
36. Keet IPM, Krijnen P, Koot M etal. Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 1993; 7: 51-57.
37. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-220.
38. Huber PJ. The behavior of maximum likelihood estimates under non-standard conditions. In: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. Berkeley: University of California Press, 1967: 221-233.
39. Durrelman S, Simon R. Flexible regression models with cubic splines. Stats Med 1989; 8: 551-561.
40. Junghans C, Low N, Chan P etal. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 1999; 13: 2547-2554.
41. Phillips AN, Lee CA, Elford J etal. More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. J Acquir Immune Deflc Syndr 1991; 4: 970-975.
42. Prins M, Robertson JR, Brettle RP etal. Do gender differences in CD4 cell counts matter? AIDS 1999; 13: 2361-2443.